COMPANY PROFILE

 RegionPuglia
 StatusUniversity

 
 PROPOSAL 

TitleItalian Title: Uso di anticorpi contro la proteina PLAC1 come biomarcatori di infertilità, kit diagnostico per la rilevazione della risposta immunitaria contro PLAC1 e uso della proteina PLAC1 in campo terapeutico e contraccettivo English Title: Use of anti-plac1protein antibodies as biomarkers of infertility
Project id.146
Reference sectorBIOTECHNOLOGY
IP Protection LevelInventors: Prof. Arcangelo Liso and Prof. Maria Matteo Applicant: Università degli Studi di Foggia Italian Patent: Identification number: ITRM20100386 (A1) on 2012-01-15; IT1401197 (B1) on 2013-07-12 European patent: Identification number: 2593789 EU granted patent on 29 April 2015 (France, Germany, Spain, United Kingdom, Monaco).
Description of the innovation project The invention concerns the use of antibodies against PLAC1 protein as biomarkers of infertility, the diagnostic kit for the detection of the immune response against PLAC1 and the potential use of PLAC1 protein in therapeutic and contraceptive fields. Although several studies have detected in women with infertility a higher prevalence of different kind of antibodies, the association between the recurrence of implantation failure and the above mentioned immune factors remains weak and unspecific. The invention could represent a novel diagnostic tool in the pre-pregnancy check‐up.
State of dev.Patent
Industrial applicationCompanies active in the diagnostic and medical fields.
Market segmentMedical or veterinary market segments, in the field of pre‐pregnancy check‐up. Data in the USA market show that 1.5 million U.S. women reported infertility; 6.7 million reported impaired ability to get pregnant or carry a baby to term; 7 million have used infertility services; These numbers are comparable to those of other industrialized nations
Advantage factorAnti-PLAC1 antibodies could represent a new and important biomarker associated with infertility: Higher levels of these antibodies associate with higher probability of repeated implantation failure. This could improve the initial diagnostic work up offered to infertile couples: A test to detect these antibodies could be recommended upfront , as women with higher levels of anti-PLAC1 antibodies could require higher number of repeated IVF cicles to overcome the “immunological barrier”
Commercial challengeWomen and couples with potential or diagnosed infertility are willing to perform specific tests. IVF centers are also interested in performing tests which offer the potential to diagnose previously undetected defects, which can require different therapeutic approaches.
Publications and Customer ReferecesMatteo M., Greco P., Levi Setti P.E., Morenghi E., De Rosario F., Massenzio F., Albani E., Totaro P., Liso A. Preliminary evidence for high anti-PLAC1 antybody levels in infertile patients with repetead unexplained implantation failure. “Placenta” (34), Ed. Elsevier, 2013, pp.335-339 (http://www.placentajournal.org/article/S0143-4004(13)00036-2/pdf)

Proposal of cooperation agreementLicensing